Yong Yu Sells 10,400 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) VP Yong Yu sold 10,400 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $21.89, for a total value of $227,656.00. Following the sale, the vice president now directly owns 106,135 shares in the company, valued at $2,323,295.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Yong Yu also recently made the following trade(s):

• On Wednesday, September 13th, Yong Yu sold 29,800 shares of Genelux stock. The stock was sold at an average price of $21.14, for a total value of $629,972.00.
• On Wednesday, August 30th, Yong Yu sold 19,800 shares of Genelux stock. The stock was sold at an average price of $24.70, for a total value of $489,060.00.

Genelux Stock Up 12.3 %

Shares of NASDAQ:GNLX traded up $2.77 during trading hours on Monday, hitting $25.38. 665,938 shares of the company’s stock traded hands, compared to its average volume of 115,093. Genelux Co. has a 1 year low of $5.35 and a 1 year high of $40.98. The business has a fifty day moving average price of $24.55 and a 200-day moving average price of $26.73.

Genelux (NASDAQ:GNLX) last announced its earnings results on Monday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.09). On average, equities analysts predict that Genelux Co. will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Maxim Group initiated coverage on Genelux in a research note on Tuesday, September 12th. They set a “buy” rating and a $40.00 price objective on the stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GNLX. Hohimer Wealth Management LLC purchased a new position in shares of Genelux during the first quarter valued at approximately $1,247,000. Axxcess Wealth Management LLC purchased a new stake in shares of Genelux in the first quarter valued at approximately $462,000. Barclays PLC purchased a new stake in shares of Genelux in the first quarter valued at approximately $920,000. Tower Research Capital LLC TRC purchased a new stake in shares of Genelux in the first quarter valued at approximately $32,000. Finally, Citigroup Inc. purchased a new stake in shares of Genelux in the first quarter valued at approximately $84,000. Hedge funds and other institutional investors own 10.77% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.